Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study

N. M. Heney, W. W. Koontz, B. Barton, M. Soloway, D. L. Trump, T. Hazra, Ronald S Weinstein, H. W. Herr, D. L. Lamm

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder. Eight weekly instillations were given followed by cystoscopy 4 weeks after the treatment was stopped. The over-all complete response rate based on cystoscopy and either biopsy or cytology was 26 per cent for thiotepa versus 39 per cent for mitomycin C (p equals 0.08). The greatest efficacy was seen in the Ta group with mitomycin C demonstrating superiority over thiotepa. Patients with negative cystoscopy and biopsy but who had positive cytology were considered to be partial responders. When partial and complete responders were combined the over-all response rate was 53 per cent for thiotepa and 63 per cent for mitomycin C (p equals 0.23). Patients with TIS appeared to respond equally to thiotepa and mitomycin C. Toxicity included urinary frequency in 22 of the 73 patients in the thiotepa arm and 31 of the 76 patients receiving mitomycin C. A rash was observed in 2 of the thiotepa group versus 14 of the mitomycin C group. Bone marrow depression occurred in 15 patients receiving thiotepa and in 12 receiving mitomycin C.

Original languageEnglish (US)
Pages (from-to)1390-1393
Number of pages4
JournalJournal of Urology
Volume140
Issue number6
StatePublished - 1988
Externally publishedYes

Fingerprint

Thiotepa
Transitional Cell Carcinoma
Mitomycin
Urinary Bladder
Prospective Studies
Cystoscopy
Cell Biology
Biopsy
Exanthema
Urinary Bladder Neoplasms
Randomized Controlled Trials
Bone Marrow

ASJC Scopus subject areas

  • Urology

Cite this

Heney, N. M., Koontz, W. W., Barton, B., Soloway, M., Trump, D. L., Hazra, T., ... Lamm, D. L. (1988). Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study. Journal of Urology, 140(6), 1390-1393.

Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder : A phase III prospective randomized study. / Heney, N. M.; Koontz, W. W.; Barton, B.; Soloway, M.; Trump, D. L.; Hazra, T.; Weinstein, Ronald S; Herr, H. W.; Lamm, D. L.

In: Journal of Urology, Vol. 140, No. 6, 1988, p. 1390-1393.

Research output: Contribution to journalArticle

Heney, NM, Koontz, WW, Barton, B, Soloway, M, Trump, DL, Hazra, T, Weinstein, RS, Herr, HW & Lamm, DL 1988, 'Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study', Journal of Urology, vol. 140, no. 6, pp. 1390-1393.
Heney, N. M. ; Koontz, W. W. ; Barton, B. ; Soloway, M. ; Trump, D. L. ; Hazra, T. ; Weinstein, Ronald S ; Herr, H. W. ; Lamm, D. L. / Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder : A phase III prospective randomized study. In: Journal of Urology. 1988 ; Vol. 140, No. 6. pp. 1390-1393.
@article{25b6d5b9e7cd4cc88a84e3dc9cf6877b,
title = "Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study",
abstract = "A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder. Eight weekly instillations were given followed by cystoscopy 4 weeks after the treatment was stopped. The over-all complete response rate based on cystoscopy and either biopsy or cytology was 26 per cent for thiotepa versus 39 per cent for mitomycin C (p equals 0.08). The greatest efficacy was seen in the Ta group with mitomycin C demonstrating superiority over thiotepa. Patients with negative cystoscopy and biopsy but who had positive cytology were considered to be partial responders. When partial and complete responders were combined the over-all response rate was 53 per cent for thiotepa and 63 per cent for mitomycin C (p equals 0.23). Patients with TIS appeared to respond equally to thiotepa and mitomycin C. Toxicity included urinary frequency in 22 of the 73 patients in the thiotepa arm and 31 of the 76 patients receiving mitomycin C. A rash was observed in 2 of the thiotepa group versus 14 of the mitomycin C group. Bone marrow depression occurred in 15 patients receiving thiotepa and in 12 receiving mitomycin C.",
author = "Heney, {N. M.} and Koontz, {W. W.} and B. Barton and M. Soloway and Trump, {D. L.} and T. Hazra and Weinstein, {Ronald S} and Herr, {H. W.} and Lamm, {D. L.}",
year = "1988",
language = "English (US)",
volume = "140",
pages = "1390--1393",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder

T2 - A phase III prospective randomized study

AU - Heney, N. M.

AU - Koontz, W. W.

AU - Barton, B.

AU - Soloway, M.

AU - Trump, D. L.

AU - Hazra, T.

AU - Weinstein, Ronald S

AU - Herr, H. W.

AU - Lamm, D. L.

PY - 1988

Y1 - 1988

N2 - A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder. Eight weekly instillations were given followed by cystoscopy 4 weeks after the treatment was stopped. The over-all complete response rate based on cystoscopy and either biopsy or cytology was 26 per cent for thiotepa versus 39 per cent for mitomycin C (p equals 0.08). The greatest efficacy was seen in the Ta group with mitomycin C demonstrating superiority over thiotepa. Patients with negative cystoscopy and biopsy but who had positive cytology were considered to be partial responders. When partial and complete responders were combined the over-all response rate was 53 per cent for thiotepa and 63 per cent for mitomycin C (p equals 0.23). Patients with TIS appeared to respond equally to thiotepa and mitomycin C. Toxicity included urinary frequency in 22 of the 73 patients in the thiotepa arm and 31 of the 76 patients receiving mitomycin C. A rash was observed in 2 of the thiotepa group versus 14 of the mitomycin C group. Bone marrow depression occurred in 15 patients receiving thiotepa and in 12 receiving mitomycin C.

AB - A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder. Eight weekly instillations were given followed by cystoscopy 4 weeks after the treatment was stopped. The over-all complete response rate based on cystoscopy and either biopsy or cytology was 26 per cent for thiotepa versus 39 per cent for mitomycin C (p equals 0.08). The greatest efficacy was seen in the Ta group with mitomycin C demonstrating superiority over thiotepa. Patients with negative cystoscopy and biopsy but who had positive cytology were considered to be partial responders. When partial and complete responders were combined the over-all response rate was 53 per cent for thiotepa and 63 per cent for mitomycin C (p equals 0.23). Patients with TIS appeared to respond equally to thiotepa and mitomycin C. Toxicity included urinary frequency in 22 of the 73 patients in the thiotepa arm and 31 of the 76 patients receiving mitomycin C. A rash was observed in 2 of the thiotepa group versus 14 of the mitomycin C group. Bone marrow depression occurred in 15 patients receiving thiotepa and in 12 receiving mitomycin C.

UR - http://www.scopus.com/inward/record.url?scp=0024239475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024239475&partnerID=8YFLogxK

M3 - Article

C2 - 3143016

AN - SCOPUS:0024239475

VL - 140

SP - 1390

EP - 1393

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -